Latest Us Market News

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Acusensus Limited reported a robust FY25 with 20% revenue growth and a significant 84% jump in total contract value, setting the stage for an ambitious FY26 forecast of up to 41% revenue increase.

Pointerra Limited reported a strong FY25 with revenue up 45% to A$11 million and a significant reduction in net loss by 68%, driven by scalable SaaS growth and key US contract wins.

Polynovo Limited reported a robust 23.3% increase in total revenue for FY25, driven by strong commercial sales growth across the US and international markets. The company is advancing its FDA PMA submission and expanding its global footprint amid strategic product development.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.

Rubicon Water reported a record FY25 revenue of A$69.1 million, driven by strong growth in the US and Rest of World markets, while reducing its net loss and building a robust project pipeline for FY26.

Rubicon Water’s FY25 results reveal strong global revenue growth led by the US and EMEA, alongside a narrowing EBITDA loss despite operational headwinds and strategic restructuring in China.

Perenti Limited has delivered record financial results for FY25, driven by strong operational performance and strategic contract wins, including its first underground mining contract in the USA. The company also improved its safety record and advanced key sustainability initiatives.

Reece Limited reported a 20% decline in EBIT for FY25, reflecting soft demand in both ANZ and US markets despite strategic branch expansions and acquisitions.

Reece Limited reported a modest revenue decline and a sharper drop in profits for FY25, reflecting subdued demand in key markets and ongoing investment in growth. The company declared a reduced fully franked dividend as it navigates a challenging housing environment.

Tourism Holdings Limited reported a statutory net loss in FY25 amid challenging market conditions but remains confident in a strategic turnaround targeting over $100 million in annualised NPAT within four years.

Cobram Estate Olives Limited (ASX – CBO) delivered a record FY2025 with a 167.8% surge in net profit and doubled US branded sales, underpinning its growth strategy and sustainability commitments.